文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

翻转剂量对比传统剂量纳武利尤单抗联合伊匹木单抗治疗黑色素瘤脑转移

Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases.
PubMed 文献 · Eur J Cancer · 2026-09-10

该回顾性研究纳入189例黑色素瘤脑转移患者,比较翻转剂量(纳武利尤单抗3mg/kg+伊匹木单抗1mg/kg,n=54)与传统剂量(纳武利尤单抗1mg/kg+伊匹木单抗3mg/kg,n=135)的疗效与安全性。翻转剂量组完成全部4次诱导治疗的患者比例更高(50.0% vs 30.4%,p=0.011),调整后PFS(aHR 0.56,95%CI 0.38-0.83,p=0.004)和OS(aHR 0.54,95%CI 0.35-0.83,p=0.005)均更长。

要点

  • 翻转剂量组完成全部4次诱导治疗比例更高(50.0% vs 30.4%,p=0.011)。
  • 调整后翻转剂量与更长PFS相关(aHR 0.56,95%CI 0.38-0.83,p=0.004)。
  • 调整后翻转剂量与更长OS相关(aHR 0.54,95%CI 0.35-0.83,p=0.005)。

核心结论

  • 在黑色素瘤脑转移真实世界队列中,翻转NIVO+IPI剂量与更多患者完成诱导治疗及更长OS和PFS相关。
  • 需前瞻性研究进一步验证翻转剂量在脑转移患者中的疗效。

研究设计与样本

  • 回顾性分析189例皮肤、黏膜、肢端或原发灶不明黑色素瘤脑转移患者,来自两家瑞典大学医院,接受NIVO+IPI治疗。
  • 翻转剂量组(NIVO3+IPI1)54例,传统剂量组(NIVO1+IPI3)135例。
  • OS和PFS采用Cox回归调整年龄、ECOG状态、基线LDH、脑病灶负荷及颅外转移部位数量。

主要发现

  • 基线特征可比,但翻转剂量组治疗前接受脑局部治疗更频繁(29.6% vs 14.8%,p=0.019)。
  • 翻转剂量组完成全部4次诱导治疗的患者更多(50.0% vs 30.4%,p=0.011)。
  • 3-4级免疫相关不良事件发生率翻转剂量组29.6% vs 传统剂量组43.0%(p=0.090)。
  • 颅内ORR 44.4% vs 30.2%(p=0.065),颅外ORR 60.9% vs 53.4%(p=0.409),全局ORR 42.6% vs 29.2%(p=0.080)。
  • 调整分析显示翻转剂量与更长PFS(aHR 0.56,95%CI 0.38-0.83,p=0.004)和OS(aHR 0.54,95%CI 0.35-0.83,p=0.005)相关。

临床怎么用

  • 对于黑色素瘤脑转移患者,翻转NIVO+IPI剂量可能提高诱导治疗完成率并改善生存,但需前瞻性验证。
  • 治疗决策时应综合考虑脑局部治疗史及免疫相关不良事件风险。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 翻转剂量组治疗前接受脑局部治疗更频繁,可能影响疗效比较。
  • 样本量有限,尤其翻转剂量组仅54例。
  • 研究仅纳入瑞典两家医院患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) is a standard option for melanoma with brain metastases. "Flipped" dosing (nivolumab 3mg/kg + ipilimumab 1mg/kg; NIVO3 +IPI1) reduces toxicity relative to traditional dosing (nivolumab 1mg/kg + ipilimumab 3mg/kg; NIVO1 +IPI3) in extracranial disease, but its efficacy in patients with brain metastases is not established. PATIENTS AND METHODS: We retrospectively analyzed 189 patients with cutaneous,mucosal, acral or unknown-primary melanoma and brain metastases treated with NIVO + IPI at two Swedish university hospitals, comparing NIVO3 + IPI1 (n = 54) and NIVO1 + IPI3 (n = 135). Outcomes were treatment exposure, global, intracranial and extracranial objective response rate (ORR), progression free survival (PFS), overall survival (OS) and safety. OS and PFS were analysed using Cox regression adjusted for age, ECOG status, baseline LDH, brain disease burden and number of extracranial metastatic sites. RESULTS: Baseline characteristics were comparable, though local brain-directed therapy before NIVO + IPI was more frequent with flipped dosing (29.6% vs 14.8%, p = 0.019). More patients completed all four induction doses with flipped dosing (50.0% vs 30.4%, p = 0.011). Grade 3-4 immune-related adverse events occurred in 29.6% vs 43.0% (p = 0.090). Intracranial ORR was 44.4% vs 30.2% (p = 0.065), extracranial ORR 60.9% vs 53.4% (p = 0.409) and global ORR 42.6% vs 29.2% (p = 0.080). In adjusted analysis, flipped dosing was associated with longer PFS (aHR 0.56, 95% CI 0.38-0.83, p = 0.004) and OS (aHR 0.54, 95% CI 0.35-0.83, p = 0.005). CONCLUSION: In this real-world cohort of melanoma patients with brain metastases, flipped NIVO + IPI dosing was associated with more patients completing induction and longer OS and PFS. A prospective evaluation is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Björkström K, Fager A, Liu C, et al. Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases. Eur J Cancer. 2026. PMID: 42743884. doi:10.1016/j.ejca.2026.117048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。